Search Results

You are looking at 21 - 30 of 237 items for :

  • "neoadjuvant chemotherapy" x
Clear All
Full access

Sherif R. Z. Abdel-Misih, Lai Wei, Al B. Benson III, Steven Cohen, Lily Lai, John Skibber, Neal Wilkinson, Martin Weiser, Deborah Schrag and Tanios Bekaii-Saab

,364), and neoadjuvant chemotherapy (n=205). This analysis is inclusive of data from September 2005 to September 2013. The clinicopathologic characteristics were analyzed and compared using chi-square test for categorical variables and the Kruskal

Full access

Deborah K. Armstrong

surgery first.” Neoadjuvant Chemotherapy For patients who are not good candidates for surgery, neoadjuvant chemotherapy is an option. In a 2010 non-inferiority study, neoadjuvant chemotherapy followed by interval debulking surgery was not inferior

Full access

Clayton A. Smith and Lisa A. Kachnic

patients with clinical T4 disease, involved CRM, or locally unresectable/medically inoperable tumors, long-course chemoRT with or without more intensive neoadjuvant chemotherapy is recommended given the available data for pathologic downstaging with

Full access

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes and Mary A. Dwyer

greater than 50 units/mL (instead of a CA-125 level >200 units/mL) is a better discriminator of cancer versus benign masses for premenopausal women. 16 Primary Treatment Using Neoadjuvant Chemotherapy The NCCN Ovarian Cancer Panel recommends up

Full access

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019

Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Jonathan S. Berek, Lee-may Chen, Mihaela Cristea, Marie DeRosa, Adam C. ElNaggar, David M. Gershenson, Heidi J. Gray, Ardeshir Hakam, Angela Jain, Carolyn Johnston, Charles A. Leath III, Joyce Liu, Haider Mahdi, Daniela Matei, Michael McHale, Karen McLean, David M. O’Malley, Richard T. Penson, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Paul Sabbatini, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns and Anita M. Engh

surgical candidate, optimal cytoreduction (residual disease <1 cm [R1] and preferably removal of macroscopic disease [R0]) appears feasible, and fertility is not a concern. Neoadjuvant chemotherapy (NACT) with interval debulking surgery (IDS) should be

Full access

S. Machele Donat

cancer . J Clin Oncol 2005 ; 23 : 4602 – 4608 . 10 Schultz PK Herr HW Zhang ZF . Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up . J Clin Oncol

Full access

Ernest S. Han and Mark Wakabayashi

ascites volume, to predict which patients may likely undergo optimal debulking procedure. Those that are not candidates for possible optimal tumor debulking surgery would then undergo neoadjuvant chemotherapy followed by interval debulking surgery if an

Full access

Joshua I. Warrick

-invasive cancers are thus managed definitively, typically with radical cystectomy, which improves survival. 4 Survival is further improved by the addition of neoadjuvant chemotherapy (NAC), usually gemcitabine and cisplatin, or MVAC (methotrexate

Full access

Siddhartha Yadav, Sri Harsha Tella, Anuhya Kommalapati, Kristin Mara, Kritika Prasai, Mohamed Hamdy Mady, Mohamed Hassan, Rory L. Smoot, Sean P. Cleary, Mark J. Truty, Lewis R. Roberts and Amit Mahipal

In addition, the current AJCC TNM staging system may not be optimal for patients undergoing neoadjuvant chemotherapy. Therefore, the current staging system is only applicable to a subset of patients with GBC who undergo upfront surgical resection. A

Full access

Jennifer Shih, Babar Bashir, Karen S. Gustafson, Mark Andrake, Roland L. Dunbrack, Lori J. Goldstein and Yanis Boumber

, she has experienced an ongoing partial response. Discussion Recurrence of TNBC with residual disease after neoadjuvant chemotherapy is common and predictable. The most common sites for breast recurrence are bones, liver, and lung, and TNBC has